Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04435184 · ClinicalTrials.gov registry record · Phase 2
Crizanlizumab for Treating COVID-19 Vasculopathy
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT04435184: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT04435184 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 54 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04435184, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this trial is to test the efficacy and safety of crizanlizumab in patients hospitalized with COVID-19.
Primary Outcome
Level of soluble P-selectin in ng/mL.
Interventions
- DRUG Crizanlizumab
- OTHER 0.9% saline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2020-07-09 |
| Est. Completion | 2021-01-04 |
| Phase | Phase 2 |
What the finished NCT04435184 record still lists
NCT04435184 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (59% lower).
The record links to 0 conditions, and to 2 interventions - of which Crizanlizumab is the first listed.
NCT04435184 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04435184 about?
NCT04435184 is a clinical study titled "Crizanlizumab for Treating COVID-19 Vasculopathy". The purpose of this trial is to test the efficacy and safety of crizanlizumab in patients hospitalized with COVID-19.
What is the current status of trial NCT04435184?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2020-07-09. Estimated completion is 2021-01-04.
What interventions are being tested in trial NCT04435184?
The interventions under investigation include: Crizanlizumab (DRUG), 0.9% saline (OTHER).
Who is sponsoring clinical trial NCT04435184?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04435184's enrollment target sits among peer trials
54 1160th of 2000 higher than 830 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI